Aimmune Therapeutics Company Profile (NASDAQ:AIMT)

About Aimmune Therapeutics (NASDAQ:AIMT)

Aimmune Therapeutics logoAimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AIMT
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.3 billion
  • Outstanding Shares: 50,535,000
Average Prices:
  • 50 Day Moving Avg: $24.71
  • 200 Day Moving Avg: $24.71
  • 52 Week Range: $14.87 - $27.31
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.90
  • P/E Growth: 0.21
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $4.70 per share
  • Price / Book: 5.46
  • EBITDA: ($106,220,000.00)
  • Return on Equity: -44.53%
  • Return on Assets: -42.00%
  • Current Ratio: 13.45%
  • Quick Ratio: 13.45%
  • Average Volume: 357,141 shs.
  • Beta: -1.03
  • Short Ratio: 27.16

Frequently Asked Questions for Aimmune Therapeutics (NASDAQ:AIMT)

What is Aimmune Therapeutics' stock symbol?

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

How were Aimmune Therapeutics' earnings last quarter?

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) released its earnings results on Tuesday, August, 8th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.01. View Aimmune Therapeutics' Earnings History.

When will Aimmune Therapeutics make its next earnings announcement?

Aimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Aimmune Therapeutics.

Where is Aimmune Therapeutics' stock going? Where will Aimmune Therapeutics' stock price be in 2017?

1 equities research analysts have issued 12 month price objectives for Aimmune Therapeutics' stock. Their predictions range from $38.00 to $42.00. On average, they anticipate Aimmune Therapeutics' share price to reach $40.00 in the next twelve months. View Analyst Ratings for Aimmune Therapeutics.

What are analysts saying about Aimmune Therapeutics stock?

Here are some recent quotes from research analysts about Aimmune Therapeutics stock:

  • 1. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (10/16/2017)
  • 2. Piper Jaffray Companies analysts commented, "Today Aimmune reported 4Q16 financial results, ending the quarter with $249M in cash. We think this cash funds the company through at least YE18. By this time, we should have results from its Phase III PALISADE program in peanut allergy and we see compelling efficacy as well as safety here as the key value-creating event for AIMT shares around YE17/early '18. By YE18, we also expect a BLA filing submitted for use in kids and teens. Based on guidance of BLA timing, and assuming the full year for BLA prep, filing and review (despite the BTD status granted to AR101), we're modestly adjusting first US peds/teens sales from 2019 to 2020, resulting in a new PT of $38. Despite this change, we continue to recommend AIMT in advance of 12-month clinical progress including, importantly, PALISADE up-dosing completion around mid'17 which we see as potentially reducing clinical risk for the program." (3/15/2017)

Who are some of Aimmune Therapeutics' key competitors?

Who are Aimmune Therapeutics' key executives?

Aimmune Therapeutics' management team includes the folowing people:

  • Mark D. McDade, Independent Chairman of the Board
  • Stephen G. Dilly M.D. Ph.D., President, Chief Executive Officer, Director
  • Eric H. Bjerkholt, Chief Financial Officer
  • Jeffrey H. Knapp, Chief Operating Officer
  • Susan E. Barrowcliffe, Senior Vice President, General Manager of Europe
  • Mary M. Rozenman, Senior Vice President - Strategy and Corporate Development
  • Douglas T. Sheehy J.D., General Counsel, Secretary
  • Sue Barrowcliffe, General Manager of Europe
  • Daniel C. Adelman M.D., Chief Medical Officer
  • Greg Behar, Independent Director

When did Aimmune Therapeutics IPO?

(AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.

How do I buy Aimmune Therapeutics stock?

Shares of Aimmune Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aimmune Therapeutics' stock price today?

One share of Aimmune Therapeutics stock can currently be purchased for approximately $25.66.

MarketBeat Community Rating for Aimmune Therapeutics (NASDAQ AIMT)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  243
MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aimmune Therapeutics (NASDAQ:AIMT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $40.00 (55.88% upside)
Consensus Price Target History for Aimmune Therapeutics (NASDAQ:AIMT)
Price Target History for Aimmune Therapeutics (NASDAQ:AIMT)
Analysts' Ratings History for Aimmune Therapeutics (NASDAQ:AIMT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/14/2017WedbushReiterated RatingOurperform$42.00LowView Rating Details
7/27/2017Piper Jaffray CompaniesSet Price TargetBuy$38.00LowView Rating Details
9/26/2016JMP SecuritiesInitiated CoverageOutperform$30.00N/AView Rating Details
8/19/2016Credit Suisse GroupReiterated RatingBuy$35.00N/AView Rating Details
5/16/2016Bank of America CorporationReiterated RatingBuyN/AView Rating Details
(Data available from 10/20/2015 forward)


Earnings History for Aimmune Therapeutics (NASDAQ:AIMT)
Earnings by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)
Earnings History by Quarter for Aimmune Therapeutics (NASDAQ AIMT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017($0.72)N/AView Earnings Details
8/8/2017Q2($0.64)($0.65)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.57)($0.52)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.47)($0.55)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.45)($0.53)ViewN/AView Earnings Details
8/10/2016Q216($0.42)($0.43)ViewN/AView Earnings Details
5/16/2016Q116($0.40)($0.37)ViewN/AView Earnings Details
3/3/2016Q415($0.35)($0.39)ViewListenView Earnings Details
11/4/2015Q3 2015($0.24)($0.36)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Aimmune Therapeutics (NASDAQ:AIMT)
2017 EPS Consensus Estimate: ($2.70)
2018 EPS Consensus Estimate: ($2.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.55)($0.55)($0.55)
Q2 20171($0.60)($0.60)($0.60)
Q3 20171($0.72)($0.72)($0.72)
Q4 20171($0.83)($0.83)($0.83)
Q1 20181($0.54)($0.54)($0.54)
Q2 20181($0.55)($0.55)($0.55)
Q3 20181($0.58)($0.58)($0.58)
Q4 20181($0.55)($0.55)($0.55)
(Data provided by Zacks Investment Research)


Dividend History for Aimmune Therapeutics (NASDAQ:AIMT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Aimmune Therapeutics (NASDAQ:AIMT)
Insider Ownership Percentage: 24.56%
Institutional Ownership Percentage: 72.90%
Insider Trades by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)
Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)
Insider Trades by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/16/2017Stephen George DillyCEOSell1,154$26.24$30,280.96View SEC Filing  
10/6/2017Stephen George DillyCEOSell4,047$26.31$106,476.57View SEC Filing  
10/5/2017Stephen George DillyCEOSell14,689$26.24$385,439.36View SEC Filing  
10/4/2017Stephen George DillyCEOSell80,110$26.23$2,101,285.30View SEC Filing  
9/25/2017Stephen George DillyCEOSell100,000$25.01$2,501,000.00View SEC Filing  
9/25/2017Susan E BarrowcliffeInsiderSell20,000$25.00$500,000.00View SEC Filing  
9/7/2017Mary M RozenmanInsiderSell30,000$22.50$675,000.00View SEC Filing  
9/6/2017Susan E BarrowcliffeInsiderSell18,390$22.00$404,580.00View SEC Filing  
7/27/2017Susan E BarrowcliffeInsiderSell500$22.00$11,000.00View SEC Filing  
7/26/2017Stephen George DillyInsiderSell50,000$21.46$1,073,000.00View SEC Filing  
7/25/2017Susan E BarrowcliffeInsiderSell6,110$22.00$134,420.00View SEC Filing  
7/21/2017Douglas T. SheehyInsiderSell7,460$21.66$161,583.60View SEC Filing  
7/17/2017Mary M RozenmanInsiderSell14,940$21.44$320,313.60View SEC Filing  
7/5/2017Mary M RozenmanInsiderSell45,060$20.85$939,501.00View SEC Filing  
7/3/2017Susan E BarrowcliffeInsiderSell15,000$20.26$303,900.00View SEC Filing  
6/23/2017Stephen George DillyInsiderSell49,400$20.21$998,374.00View SEC Filing  
5/12/2017Eric BjerkholtCFOBuy5,000$19.84$99,200.00View SEC Filing  
5/10/2017Stephen George DillyInsiderSell600$20.15$12,090.00View SEC Filing  
4/3/2017Warren L DesouzaCFOSell15,000$21.58$323,700.00View SEC Filing  
3/21/2017Warren L DesouzaCFOSell10,000$22.95$229,500.00View SEC Filing  
11/4/2016Mary M RozenmanInsiderSell24,096$17.60$424,089.60View SEC Filing  
10/5/2016Mary M RozenmanInsiderSell25,000$16.80$420,000.00View SEC Filing  
9/8/2016Mary M RozenmanInsiderSell30,000$16.80$504,000.00View SEC Filing  
5/31/2016Foresite Capital Fund Ii, L.P.Major ShareholderSell240,000$15.23$3,655,200.00View SEC Filing  
3/29/2016Longitude Capital Partners Ii,Major ShareholderBuy78,504$13.87$1,088,850.48View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Aimmune Therapeutics (NASDAQ:AIMT)
Latest Headlines for Aimmune Therapeutics (NASDAQ:AIMT)
DateHeadline logoAimmune Therapeutics (AIMT) to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings - - October 19 at 9:15 PM logoAimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings - October 19 at 4:13 PM logoAimmune Therapeutics, Inc. (AIMT) CEO Stephen George Dilly Sells 1,154 Shares - October 18 at 8:56 PM logo[$$] Aimmune, DBV: Fighting Over More Than Peanuts - October 18 at 4:53 PM logoAimmune Therapeutics And DBV Technologies: 2 Different ... - Seeking Alpha - October 18 at 2:38 AM logoAimmune Therapeutics, Inc. (AIMT) Expected to Post Earnings of -$0.72 Per Share - October 17 at 4:30 PM logoAimmune Therapeutics (AIMT) Announces Pact to Study AR101 with Regeneron (REGN) and Sanofi's (SNY) Dupilumab for Peanut Allergy - October 17 at 2:34 AM logoAimmune Therapeutics (AIMT) Announces Pact to Study AR101 with Regeneron (REGN) and Sanofi's (SNY ... - - October 16 at 9:33 PM logoAimmune Therapeutics, Inc. (AIMT) Stock Rating Upgraded by Zacks Investment Research - October 16 at 8:44 PM logoDrugmakers Are Planning to Start a Phase 2 Trial to Cure Peanut Allergy - October 16 at 4:31 PM logoAimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy - October 16 at 4:31 PM logoAimmune teams with Regeneron, Sanofi on peanut allergy drug - October 16 at 4:31 PM logoInteresting AIMT Put And Call Options For November 17th - October 13 at 3:35 PM logoIs the Options Market Predicting a Spike in Aimmune Therapeutics (AIMT) Stock? - October 9 at 4:42 PM logoCritical Analysis: Aimmune Therapeutics (AIMT) versus The Competition - October 8 at 4:24 PM logoAimmune Therapeutics, Inc. (AIMT) CEO Stephen George Dilly Sells 4,047 Shares - October 6 at 8:16 PM logoInsider Selling: Aimmune Therapeutics, Inc. (AIMT) CEO Sells 14,689 Shares of Stock - October 6 at 7:46 PM logoStephen George Dilly Sells 80,110 Shares of Aimmune Therapeutics, Inc. (AIMT) Stock - October 6 at 7:24 PM logoAimmune Therapeutics (AIMT) versus Its Rivals Head-To-Head Review - September 30 at 2:24 PM logoReviewing Aimmune Therapeutics (AIMT) and Its Rivals - September 29 at 2:30 AM logoAimmune Therapeutics (AIMT) in Focus: Stock Moves 6.3% Higher - Nasdaq - September 28 at 1:13 AM logoReviewing Aimmune Therapeutics (AIMT) and Its Competitors - September 27 at 10:20 PM logoAimmune Therapeutics Inc (AIMT) Insider Susan E. Barrowcliffe Sells 20,000 Shares - September 27 at 7:44 PM logoStephen George Dilly Sells 100,000 Shares of Aimmune Therapeutics Inc (AIMT) Stock - September 27 at 7:26 PM logoHead to Head Comparison: Aimmune Therapeutics (AIMT) vs. Its Competitors - September 22 at 9:02 AM logoComparing Aimmune Therapeutics (AIMT) and Its Rivals - September 20 at 4:12 PM logoCritical Review: Aimmune Therapeutics (AIMT) and Its Rivals - September 19 at 6:12 PM logoFinancial Survey: Aimmune Therapeutics (AIMT) and Its Peers - September 18 at 12:02 PM logoCheck-Cap (CHEK) vs. Aimmune Therapeutics (AIMT) Critical Review - September 16 at 10:32 AM logoAimmune Making Headway In Food Allergy Market - Seeking Alpha - Seeking Alpha - September 12 at 3:53 PM logoInsider Selling: Aimmune Therapeutics, Inc. (AIMT) Insider Sells 30,000 Shares of Stock - September 11 at 7:30 PM logoAimmune Therapeutics, Inc. (AIMT) Insider Sells $404,580.00 in Stock - September 7 at 7:42 PM logoAimmune Therapeutics to Participate in Three Investor Conferences in September - September 6 at 3:36 PM logoAimmune Therapeutics, Inc. (AIMT) Given Consensus Recommendation of "Hold" by Brokerages - September 6 at 7:04 AM logoCritical Review: Repligen Corporation (RGEN) and Aimmune Therapeutics (AIMT) - September 1 at 6:06 AM logoContrasting AbbVie (ABBV) and Aimmune Therapeutics (AIMT) - August 30 at 12:18 PM logoFinancial Contrast: Aimmune Therapeutics (AIMT) and Advanced Accelerator Applications (AAAP) - August 23 at 4:26 AM logo Brokerages Expect Aimmune Therapeutics, Inc. (AIMT) Will Announce Earnings of -$0.72 Per Share - August 22 at 2:22 PM logoQ3 2017 EPS Estimates for Aimmune Therapeutics, Inc. (AIMT) Decreased by Wedbush - August 16 at 7:14 AM logoAimmune Therapeutics, Inc. (NASDAQ:AIMT) Receives Ourperform Rating from Wedbush - August 14 at 11:41 AM logoAimmune Therapeutics, Inc. (NASDAQ:AIMT) Given Consensus Recommendation of "Hold" by Brokerages - August 12 at 4:32 AM logoAimmune Therapeutics (AIMT) Investigational Treatment for Peanut Allergy Featured in Science Translational Medicine Publication - August 10 at 5:06 PM logoAimmune Therapeutics, Inc. (AIMT) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - August 9 at 4:34 PM logoAimmune Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16th - August 9 at 3:54 PM logoAimmune Therapeutics Announces Second Quarter 2017 Financial Results - August 8 at 8:37 PM logoAimmune Therapeutics reports 2Q loss - August 8 at 8:37 PM logoAimmune Therapeutics’ Investigational Treatment for Peanut Allergy Featured in Science Translational Medicine Publication on Discovery of New TH2 Cell Subset Specific to Allergy - August 8 at 3:36 PM logoCritical Comparison: Aimmune Therapeutics (NASDAQ:AIMT) versus AbbVie (ABBV) - August 5 at 8:30 AM logo Brokerages Anticipate Aimmune Therapeutics, Inc. (AIMT) to Post -$0.64 Earnings Per Share - August 4 at 8:26 AM logoAimmune Therapeutics, Inc. (AIMT) to Release Earnings on Tuesday - August 1 at 7:17 AM



Aimmune Therapeutics (AIMT) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.